Switch Case Study: Alli Review Contrasts OTC, Rx Division Perspectives
This article was originally published in The Tan Sheet
Executive Summary
Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails and other documents, the publication strives to illuminate the agency's decision-making process.
You may also be interested in...
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice